APOBEC3G antibody

GeneTex

APOBEC3G antibody

9

WB: 5 microg/mL. IHC-P: 1 microg/mL. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

Western Blot, ELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Polyclonal

1 mg/ml

Unconjugated

APOBEC3G

apolipoprotein B mRNA editing enzyme catalytic subunit 3G

A3G; APOBEC-related cytidine deaminase; APOBEC-related protein 9; apolipoprotein B editing enzyme catalytic polypeptide-like 3G; apolipoprotein B mRNA editing enzyme cytidine deaminase; apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G; apolipoprotein B mRNA-editing enzyme catalytic polypeptide 3G; ARCD; ARP9; ARP-9; bK150C2.7; CEM15; CEM-15; deoxycytidine deaminase; dJ494G10.1; DNA dC->dU editing enzyme; DNA dC->dU-editing enzyme APOBEC-3G; MDS019; phorbolin-like protein MDS019

Rabbit

IgG

DNA dC->dU-editing enzyme APOBEC-3G

The Apoliprotein B mRNA-editing, enzyme-catalytic, polypeptide-like (APOBEC) 3 is a multi-isoform member of the cytidine deaminase family of enzymes that act on monomeric nucleoside and nucleotide substrates (1). Similar to TRIM5alpha which targets incoming retroviral capsids, APOBEC3 plays a major role in cellular defense against retroviral infection (2,3) as at least two isoforms, APOBEC3G and to a lesser extent APOBEC3F, can be incorporated HIV-1 virions and induce hypermutation in the newly synthesized viral DNA and thus destabilize the viral genome (4,5). This innate mechanism of retroviral resistance is counteracted by the HIV-1 Vif protein by inducing the ubiquitization and degradation of APOBEC3G; a single amino acid substitution (D128K) blocks APOBEC3G depletion without affecting its inhibitory activity (6).

-20°C or -80°C,2°C to 8°C

12352203